Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for polyarticular juvenile idiopathic arthritis has been reported in the published literature.
9 FDA-approved treatments are available for polyarticular juvenile idiopathic arthritis, including METHOTREXATE (RASUVO, approved 2014), ADALIMUMAB-ADBM (ADALIMUMAB-ADBM, approved 2017), and ADALIMUMAB-ATTO (AMJEVITA, approved 2016). An additional 1 compound holds orphan drug designation.
Brand Name | Generic Name | Mechanism | Approved |
|---|
3 clinical trials registered, 2 recruiting. Interventions under study include drug therapy, other interventions, and biologic therapy. Pipeline includes 1 PHASE1. Research is sponsored by a mix of industry and academic institutions.
76 publications have been identified in PubMed for polyarticular juvenile idiopathic arthritis. Research spans Epidemiology / Natural History (29%), Review / Meta-Analysis (24%), and Case Report / Case Series (12%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 22 |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 8:42 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
ADALIMUMAB-RYVK | ADALIMUMAB-RYVK | — | 2024 | Available |
JYLAMVO | METHOTREXATE | — | 2022 | Available |
ABRILADA | ADALIMUMAB-AFZB | — | 2019 | Available |
HADLIMA | ADALIMUMAB-BWWD | — | 2019 | Available |
ADALIMUMAB | ADALIMUMAB-ADAZ | — | 2018 | Available |
ADALIMUMAB-ADBM | ADALIMUMAB-ADBM | — | 2017 | Available |
XATMEP | METHOTREXATE | — | 2017 | Available |
AMJEVITA | ADALIMUMAB-ATTO | — | 2016 | Available |
RASUVO | METHOTREXATE | — | 2014 | Available |
OTREXUP | METHOTREXATE | — | 2013 | Available |
CIMZIA | CERTOLIZUMAB PEGOL | — | 2008 | Available |
ENBREL | ETANERCEPT | — | 1998 | Available |
The following drugs have received orphan drug designation from the FDA for polyarticular juvenile idiopathic arthritis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor | Designated | Exclusivity End | Designation Status |
|---|---|---|---|---|---|
SIMPONI ARIA® | golimumab | Janssen Research & Development, LLC | 2015 | 2027 | Designated (drug approved for other indication) |
Gene therapy approaches for polyarticular juvenile idiopathic arthritis have been reported in the published literature.
3 trials found
29%
Research summaries | 18 | 24% |
Patient case studies | 9 | 12% |
Clinical study results | 8 | 11% |
Testing and diagnosis research | 7 | 9% |
Laboratory research | 6 | 8% |
Other research | 4 | 5% |
New treatment approaches | 1 | 1% |
Atamyıldız Uçar S (2026). [PMID: 41723586](https://pubmed.ncbi.nlm.nih.gov/41723586/). *Expert Opin Biol Ther*. [Epidemiology / Natural History]
Ata EB (2026). [PMID: 41533222](https://pubmed.ncbi.nlm.nih.gov/41533222/). *Clin Rheumatol*. [Epidemiology / Natural History]
Das PK (2026). [PMID: 41895033](https://pubmed.ncbi.nlm.nih.gov/41895033/). *Biologicals*. [Review / Meta-Analysis]
Yildiz M (2026). [PMID: 41621940](https://pubmed.ncbi.nlm.nih.gov/41621940/). *J Rheumatol*. [Diagnostic / Biomarker]
Aida Y (2026). [PMID: 42033659](https://pubmed.ncbi.nlm.nih.gov/42033659/). *Int J Rheum Dis*. [Other]
Gundogmus F (2026). [PMID: 41780543](https://pubmed.ncbi.nlm.nih.gov/41780543/). *Klin Padiatr*. [Review / Meta-Analysis]
Liu P (2026). [PMID: 41557167](https://pubmed.ncbi.nlm.nih.gov/41557167/). *Clin Rheumatol*. [Epidemiology / Natural History]
Abedeen ZU (2026). [PMID: 41578476](https://pubmed.ncbi.nlm.nih.gov/41578476/). *Medicine (Baltimore)*. [Case Report / Case Series]
Brutzkus JC (2026). [PMID: 30247840](https://pubmed.ncbi.nlm.nih.gov/30247840/). *Unknown Journal*. [Epidemiology / Natural History]
Padda IS (2026). [PMID: 35015417](https://pubmed.ncbi.nlm.nih.gov/35015417/). *Unknown Journal*. [Epidemiology / Natural History]
AI-curated news mentioning polyarticular juvenile idiopathic arthritis
Updated Sep 14, 2026
A recent study published in PubMed examines the incidence and risk factors associated with adverse events in children with juvenile idiopathic arthritis. The findings aim to enhance management strategies in real-world care settings.
A randomized placebo-controlled trial found that probiotic supplementation increases fecal TLR4 agonists but does not improve disease activity in juvenile idiopathic arthritis. This study contributes to understanding the role of probiotics in managing this condition.
A qualitative study explores the stress and coping mechanisms of primary caregivers managing pain in children with juvenile idiopathic arthritis. Insights from this research may inform support strategies for caregivers in similar situations.